Search Results - "GREINWALD, R"
-
1
norUrsodeoxycholic acid improves cholestasis in primary sclerosing cholangitis
Published in Journal of hepatology (01-09-2017)“…[Display omitted] •There is an urgent need for novel drugs for PSC.•In this phase II clinical trial, norUDCA reduced serum ALP levels within 12weeks.•norUDCA’s…”
Get full text
Journal Article -
2
Peripheral blood eosinophils and other non‐invasive biomarkers can monitor treatment response in eosinophilic oesophagitis
Published in Alimentary pharmacology & therapeutics (01-11-2015)“…Summary Background Monitoring of the treatment response in eosinophilic oesophagitis (EoE) requires structured endoscopical and histological examination of the…”
Get full text
Journal Article -
3
Editorial: mesalazine to prevent recurrent acute diverticulitis—the final nail in the coffin. Authors’ reply
Published in Alimentary pharmacology & therapeutics (01-08-2017)“…Linked ContentThis article is linked to Gracie and Ford et al and Kruis and Greinwald papers. To view these articles visit https://doi.org/10.1111/apt.14180…”
Get full text
Journal Article -
4
Randomised clinical trial: mesalazine (Salofalk granules) for uncomplicated diverticular disease of the colon – a placebo‐controlled study
Published in Alimentary pharmacology & therapeutics (01-04-2013)“…Summary Background Robust evidence regarding medical intervention for symptomatic uncomplicated colonic diverticular disease (DD) is sparse. Aim To investigate…”
Get full text
Journal Article -
5
Once daily versus three times daily mesalazine granules in active ulcerative colitis: a double-blind, double-dummy, randomised, non-inferiority trial
Published in Gut (01-02-2009)“…To determine the therapeutic equivalence and safety of once daily (OD) versus three times daily (TID) dosing of a total daily dose of 3 g Salofalk (mesalazine)…”
Get more information
Journal Article -
6
Randomised clinical trial: mesalazine versus placebo in the prevention of diverticulitis recurrence
Published in Alimentary pharmacology & therapeutics (01-08-2017)“…Summary Background Previous studies have reached conflicting conclusions regarding the efficacy of mesalazine in the prevention of recurrent diverticulitis…”
Get full text
Journal Article -
7
Randomised clinical trial: a comparative dose‐finding study of three arms of dual release mesalazine for maintaining remission in ulcerative colitis
Published in Alimentary pharmacology & therapeutics (01-02-2011)“…Aliment Pharmacol Ther 2011; 33: 313–322 Summary Background Comparative data regarding different regimens of oral mesalazine (mesalamine) for maintaining…”
Get full text
Journal Article -
8
Mesalazine granules are superior to Eudragit‐L‐coated mesalazine tablets for induction of remission in distal ulcerative colitis – a pooled analysis
Published in Alimentary pharmacology & therapeutics (01-11-2011)“…Aliment Pharmacol Ther 2011; 34: 1115–1122 Summary Background Different oral formulations of ‘mesalazine (mesalamine)’ may have different efficacy in distal…”
Get full text
Journal Article -
9
-
10
Clinical trial: randomized‐controlled clinical study comparing the efficacy and safety of a low‐volume vs. a high‐volume mesalazine foam in active distal ulcerative colitis
Published in Alimentary pharmacology & therapeutics (01-11-2007)“…Summary Background Rectally administered mesalazine (mesalamine; 5‐aminosalicylic acid) is the first‐line therapy for treatment of distal ulcerative colitis…”
Get full text
Journal Article -
11
Budesonide foam versus budesonide enema in active ulcerative proctitis and proctosigmoiditis
Published in Alimentary pharmacology & therapeutics (15-01-2006)“…Summary Background Rectal budesonide is an effective treatment of active ulcerative proctitis or proctosigmoiditis. Aim To compare the therapeutic efficacy,…”
Get full text
Journal Article -
12
Colonic spread and serum pharmacokinetics of budesonide foam in patients with mildly to moderately active ulcerative colitis
Published in Alimentary pharmacology & therapeutics (01-09-2005)“…Summary Background : Local treatment with foams in patients suffering from ulcerative proctitis or proctosigmoiditis is considered a rational treatment option…”
Get full text
Journal Article -
13
Comparison of the efficacy and safety of Eudragit‐L‐coated mesalazine tablets with ethylcellulose‐coated mesalazine tablets in patients with mild to moderately active ulcerative colitis
Published in Alimentary pharmacology & therapeutics (01-04-2006)“…Summary Background There are no comparative studies of coated mesalazine. Aim To compare the efficacy and tolerability of Eudragit‐L‐ and…”
Get full text
Journal Article -
14
A double‐blind dose‐escalating trial comparing novel mesalazine pellets with mesalazine tablets in active ulcerative colitis
Published in Alimentary pharmacology & therapeutics (15-01-2005)“…Summary Background : Mesalazine as the treatment standard for ulcerative colitis can be applied in different galenical preparations. Aim : A novel formulation…”
Get full text
Journal Article -
15
6‐Thioguanine — efficacy and safety in chronic active Crohn's disease
Published in Alimentary pharmacology & therapeutics (15-02-2003)“…Summary Background : Azathioprine and mercaptopurine are commonly used in chronic active Crohn's disease. They share the disadvantage of a delayed onset of…”
Get full text
Journal Article -
16
Thioguanine‐nucleotides do not predict efficacy of tioguanine in Crohn's disease
Published in Alimentary pharmacology & therapeutics (15-06-2004)“…Summary Background : 6‐Thioguanine‐nucleotides seem to be the active metabolites of thiopurine therapy, and their monitoring has been considered a useful tool…”
Get full text
Journal Article -
17
Maintenance treatment with budesonide 6 mg versus 9 mg once daily in patients with Crohn's disease in remission
Published in Netherlands journal of medicine (01-10-2007)“…In previous trials, budesonide 6 mg/day was able to prolong the time to relapse in patients with quiescent Crohn's disease and budesonide 9 mg/day was…”
Get full text
Journal Article -
18
Feasibility and response to budesonide as topical corticosteroid therapy for acute intestinal GVHD
Published in Bone marrow transplantation (Basingstoke) (01-12-1999)“…Therapy of acute intestinal GVHD is still one of the main challenges after allogeneic transplantation. Increasing systemic immunosuppression (IS) is the first…”
Get full text
Journal Article -
19
Oral Budesonide Significantly Improves Water Absorption in Patients with Ileostomy for Crohn Disease
Published in Scandinavian journal of gastroenterology (01-03-2003)“…Background: In addition to their anti-inflammatory effects, steroids influence electrolyte and water transport systems in the intestinal mucosa. This study…”
Get full text
Journal Article -
20
A placebo-controlled randomised trial of budesonide for PBC following an insufficient response to UDCA
Published in Journal of hepatology (01-02-2021)“…In patients with primary biliary cholangitis (PBC), the efficacy of budesonide, a synthetic corticosteroid displaying high first-pass metabolism, is…”
Get full text
Journal Article